Literature DB >> 16211883

Leptomeningeal metastases from leukemias and lymphomas.

Craig P Nolan1, Lauren E Abrey.   

Abstract

Leptomeningeal dissemination of lymphoma and leukemia differs from that of solid tumors in a number of clinically important aspects. Specific histologic variants of lymphoma and leukemia have such a high incidence of cerebrospinal fluid (CSF) dissemination that assessing CSF cytology at diagnosis is crucial and prophylactic therapy of the CSF compartment is required. Furthermore, while the overall prognosis for patients with leptomeningeal metastases from leukemia and lymphoma is similar to solid tumors, selected patients have excellent response to therapy and attain durable remission. Therefore, aggressive treatment is warranted.

Entities:  

Mesh:

Year:  2005        PMID: 16211883     DOI: 10.1007/0-387-24199-x_4

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  3 in total

Review 1.  Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment.

Authors:  Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Expert Rev Mol Med       Date:  2015-01-30       Impact factor: 5.600

2.  Detection of cancer cells in the cerebrospinal fluid: current methods and future directions.

Authors:  Cody L Weston; Michael J Glantz; James R Connor
Journal:  Fluids Barriers CNS       Date:  2011-03-03

Review 3.  Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors.

Authors:  Lori A Ramkissoon; Worthy Pegram; James Haberberger; Natalie Danziger; Glenn Lesser; Roy Strowd; Sonika Dahiya; Thomas J Cummings; Wenya Linda Bi; Malak Abedalthagafi; Pratheesh Sathyan; Kimberly McGregor; Prasanth Reddy; Eric Severson; Erik Williams; Douglas Lin; Claire Edgerly; Richard S P Huang; Amanda Hemmerich; James Creeden; Charlotte Brown; Jeffrey Venstrom; Priti Hegde; Jeffrey S Ross; Brian M Alexander; Julia Elvin; Shakti H Ramkissoon
Journal:  Front Neurol       Date:  2020-10-19       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.